Skip to Main Content

Tofacitinib for Treatment of Moderate COVID-19 (I-TOMIC)

Conditions

Diseases of the Respiratory Systems | COVID-19 Inpatient

Phase COVID-NA

What is the purpose of this trial?

The purpose of this randomized, double blinded, placebo controlled study is to assess the efficacy and safety of tofacitinib in hospitalized adult (18-65 years old) patients with SARS-CoV-2 and pneumonia who require supplemental oxygen and have serologic markers of inflammation but do not need mechanical ventilation.

  • Trial with
    Yale University School of Medicine
  • Start Date
    09/02/2020
  • End Date
    12/30/2020
Trial Image

For more information about this study, contact:

Danielle Peterson

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    10/02/2020
  • Study HIC
    #2000027848